Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo
- 1 Service de Maladies Infectieuses et de Pneumologie, CHU Sylvanus Olympio, Lomé, Togo
- 2 Service de Maladies Infectieuses et de Pneumologie, CHU Sylvanus Olympio, Lomé, Togo
- 3 Service de Maladies Infectieuses et de Pneumologie, CHU Sylvanus Olympio, Lomé, Togo
- 4 Service de Maladies Infectieuses et de Pneumologie, CHU Sylvanus Olympio, Lomé, Togo
Abstract
Objective : To evaluate the virological status of in eligible HIV patients for anti - retroviral therapy based on the criterion of CD4+ T lymphocytes rate over than 350/μl of blood . Method : This is a prospective study which was conducted from November 2011 to July 2012 in the tropical and infectious disease department of CHU Sylvanus Olympio of Lomé. All HIV-1 infected patients whose CD4+ T lymphocytes rate was ≥350/μl of blood were retained. The count of CD4+ T lymphocytes was made by cytometer FACSCalibur ? flow of BD biosciences and the determination of viral load was achieved by NASBA laboratory method of Biomérieux. Results : We have recruited 102 PLWHA aged between 19 and 58 years with a median of 35 years. Biologically, 102 patients had a T-CD4 rate between 355 and 432/μl of blood. The determination of viral load showed a very high viral replication more than 10,000 copies / ml among all patients and 28 (27.5%) patients had a viral load > 100,000 copies / ml of blood . Conclusion : Our results argue for a reconsideration of the criteria for starting antiretroviral therapy in Togo by including virological data if necessary in patients with T-CD4 rate below 500/μl of blood.
- PNLS-INFO No. 001/2007 PNLS-Togo, 2007, 1-5.
- PNLS, “Directives Pour une Prise en Charge Avec les Médicaments Antirétroviraux (ARV) au Togo,” 2004, pp 3-9.
- PNLS, “Guide National de la Prise en Charge Médiacle du VIH/SIDA: Affections Opportunistes et Traitement par les Antirétroviraux,” 2004, p. 104.
- OMS, “Recommendation Pour une Approche de Santé Publique: Améliorer L’accès aux Traitements Antirétroviraux dans les Pays à Ressources Limitées,” 2002, pp. 8-9.
- ONUSIDA, “Rapport sur l’épidémie Mondiale de SIDA,” ONUSIDA, Genève, 2006, pp. 3-4.
- R. D. Moore and J. C. Keruly, “CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Person with Sustained Virologic Suppression,” Clinical Infectious Diseases, Vol. 44, No. 3, 2007, pp. 441-446. http://dx.doi.org/10.1086/510746
- J. V. Baker, G. Peng, J. Rapkin, et al., “CD4+ Count and Risk of Non-AIDS Diseases Following Initial Treatment for HIV Infection,” AIDS, Vol. 22, No. 7, 2008, pp. 841-888. http://dx.doi.org/10.1097/QAD.0b013e3282f7cb76
- S. Emery, J. A. Neuhaus, A. N. Phillips, et al., “Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study,” Journal of Infectious Diseases, Vol. 197, No. 8, 2008, pp. 1133-1144. http://dx.doi.org/10.1086/586713
- HIV-CAUSAL Collaboration, et al., “The Effect of Combined Antiretroviral Therapy on the Overall Mortality of HIV-Infected Individuals,” AIDS, Vol. 24, No. 1, 2010, pp. 123-137. http://dx.doi.org/10.1097/QAD.0b013e3283324283
- M. Guiguet, F. Boue, J. Cadranel, J. M. Lang, E. Rosenthal and D. Costagliola, “Effect of Immunodeficiency, HIV Viral Load, and Antiretroviral Therapy on the Risk of Individual Malignancies (FHDH-ANRS CO4): A Prospective Cohort Study,” Lancet Oncology, Vol. 10, No. 12, 2009, pp. 1152-1159. http://dx.doi.org/10.1016/S1470-2045(09)70282-7
- C. F. Kelley, C. M. Kitchen, P. W. Hunt, et al., “Incomplete Peripheral CD4+ Cell Count Restoration in HIV Infected Patients Receiving Long-Term Antiretroviral Treatment,” Clinical Infectious Diseases, Vol. 48, No. 6, 2009, pp. 787-794. http://dx.doi.org/10.1086/597093
- M. Egger, M. May, G. Chêne, et al., “Prognosis of HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies,” Lancet, Vol. 360, No. 9327, 2002, pp. 119-129. http://dx.doi.org/10.1016/S0140-6736(02)09411-4